Bayer spinning out anti-infectives research

Continuing the restructuring that started in 2001, Bayer (FSE:BAYG; BAY) plans to spin out the anti-infectives research unit of its pharmaceuticals division into a new company that will be majority owned by Santo (Stuttgart, Germany). BAYG will retain a minority stake. The newco will take over various R&D projects, IP and licenses from BAYG and will develop treatments for human cytomegalovirus (CMV), HCV, HIV, herpes simplex virus (HSV) and Gram-positive bacterial infections. The deal is expected to close next quarter. ...